Search Within

Center for Hematologic Malignancies

Formats
  1. Journal Article (6195)
  2. Meeting Abstract (6166)
  3. Review (401)
  4. Book Section (216)
  5. Editorial (172)
  6. Research Letter (160)
  7. Guidelines (83)
  8. Conference Paper (70)
  9. Correspondence (61)
  10. Miscellaneous (19)
  11. Book Whole (10)
Groups
  1. Department of Medicine (11094)
  2. Hematologic Malignancies, Division of (10645)
  3. GSK Faculty (5449)
  4. Adult Leukemia (3723)
  5. Sloan Kettering Institute Faculty (3375)
  6. Hematologic Malignancies Research (3005)

More Groups

People
  1. Sergio Giralt (1069)
  2. Miguel-Angel Perales (946)
  3. Ross Levine (787)
  4. Andrew Zelenetz (785)
  5. Steven Horwitz (671)
  6. Martin Tallman (655)

More People

Years
  1. 2025 (317)
  2. 2024 (704)
  3. 2023 (877)
  4. 2022 (830)
  5. 2021 (802)
  6. 2020 (874)

More Years

Publications
  1. Blood (3413)
  2. Journal of Clinical Oncology (869)
  3. Biology of Blood and Marrow Transplantation (602)
  4. Clinical Lymphoma, Myeloma and Leukemia (304)
  5. Cancer Research (300)
  6. Haematologica (268)

More Publications

Publishers
  1. American Society of Hematology (3684)
  2. Elsevier Inc. (1669)
  3. Nature Publishing Group (1118)
  4. American Society of Clinical Oncology (918)
  5. American Association for Cancer Research (680)
  6. Wiley Blackwell (437)

More Publishers

Results (13553)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia
    Meeting Abstract

    Sadelain, M.; Brentjens, R.; Davila, M.; Riviere, I.; Wang, X. Y.; Bartido, S.; Park, J.; Bouhassira, D.; Curran, K.; Chung, S.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • AFM13: An antigen specific immunotherapy for the treatment of CD30+ malignancies: Results of first-in-man study in relapsed/refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Rothe, A.; Reiners, K. S.; Topp, M. S.; Younes, A.; von Tresckow, B.; Hummel, H. D.; Kessler, J.; Ravic, M.; Marschner, J. P.; von Strandmann, E. P.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • RNAi mouse models: Revolutionizing drug discovery in vivo
    Meeting Abstract

    Premsrirut, P. K.; Yoon, B.; Pesic, M.; Dow, L. E.; Zuber, J.; Lowe, S. W.; Hannon, G. J.; Zender, L.; Fellmann, C.
    Cancer Research (2014)

    Fulltext@MSK | Save
  • Dual function HDAC and PI3K inhibitor, CUDC-907 affects cancer cells and the tumor microenvironment in hematological malignancies
    Meeting Abstract

    Ma, A. W.; Atoyan, R.; Younes, A.; Flinn, I. W.; Oki, Y.; Copeland, A.; Berdeja, J. G.; Laliberte, R.; Viner, J.; Samson, M. E. S.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors
    Meeting Abstract

    Lito, P.; Saborowski, A.; Yue, J.; Solomon, M.; Joseph, E.; Fellman, C.; Ohara, K.; Morikami, K.; Miura, T.; Lucas, C.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • Development and validation of a clinical next generation sequencing-based assay for hematologic malignancies
    Meeting Abstract

    Lipson, D.; Nahas, M. K.; Otto, G. A.; He, J.; Wang, K.; Knapp, K. M.; Brennan, K. W.; Donahue, A. L.; Young, L. E.; Young, G.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • Context specific effects of the BRAFV600E mutation on hematopoiesis identifies novel models of BRAF mutant hematopoietic disorders
    Meeting Abstract

    Kim, E.; Chung, S. S.; Park, J. H.; Chung, Y. R.; Lito, P.; Feldstein, J.; Hu, W. H.; Beguilin, W.; Monette, S.; Duy, C.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • RNAi screen identifies therapeutic targets in hepatocellular carcinoma
    Meeting Abstract

    Huang, C. H.; Lujambio, A.; Zuber, J.; Kitzing, T.; Tschaharganeh, D. F.; Destanchina, E.; Lowe, S. W.
    Cancer Research (2014)

    Fulltext@MSK | Save
  • Preclinical pharmacology and clinical efficacy of AZD9150 (ISIS-STAT3Rx), a potent next-generation antisense oligonucleotide inhibitor of STAT3
    Meeting Abstract

    Hong, D.; Kim, Y.; Younes, A.; Nemunaitis, J.; Fowler, N.; Hsu, J.; Zhou, T. Y.; Fayad, L.; Zhang, N.; Piha-Paul, S.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • Loss of PTEN leads to clinical resistance to the PI3K alpha inhibitor BYL719 and provides evidence of convergent evolution under selective therapeutic pressure
    Meeting Abstract

    Castel, P.; Juric, D.; Won, H.; Ainscough, B.; Ellis, H.; Ebbesen, S.; Griffith, M.; Griffith, O.; Iyer, G.; Sgroi, D.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save